Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia

Journal of Anxiety Disorders

Volumn 10, Issue 4, 1996, Pages 219-242

  Sharp, Donald M ^b   Power, Kevin G ^c   Simpson, R J ^c   Swanson, Vivien ^c   Moodie, Eleanor ^c   Anstee, Julie A ^a   Pharm, B ^a   Ashford, J J ^a  

^a Duphar Laboratories Ltd   (United Kingdom)

^b UNIVERSITY OF STIRLING   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; PLACEBO;

ADULT; AGORAPHOBIA; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANIC; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SELF REPORT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 8944245858     PISSN: 08876185     EISSN: None     Source Type: Journal    
DOI: 10.1016/0887-6185(96)00008-4     Document Type: Article

References (39)

1. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: Author.
2. Ashcroft, G. W. (1987). Consensus statement: panic disorder. British Journal of Psychiatry, 150, 557-558.
3. Barlow, D. H. (1988). Anxiety and its disorders: The nature and treatment of anxiety and panic. New York: Guilford Press.
4. Black, D. W., Wesner, R., Bowers, W., & Gabel, J. (1993). A comparison of Fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Archives of General Psychiatry, 50, 44-50.
5. Chambless, D. L., & Gillis, M. M. (1993). Cognitive therapy of anxiety disorders. Journal of Consulting and Clinical Psychology, 61, 248-260.
6. Clark, D. M., & Ehlers, A. (1993). An overview of the cognitive theory and treatment of panic disorder. Applied and Preventive Psychology, 2, 131-139.
7. Den Boer, J. A., Westenberg, H. G. M., Kamerbeck, W. D. J., Verhoeven, W. M. A., & Kahn, R. S. (1987). Effect of serotonin uptake inhibitors in anxiety disorders: A double-blind comparison of chlomipramine and Fluvoxamine. International Clinical Psychopharmacology, 2, 21-32.
8. Den Boer, J. A., & Westenberg, H. G. M. (1988). Effect of serotonin and noradrenaline uptake inhibitor in panic disorder: A double-blind comparative study with Fluvoxamine and maprotiline. International Clinical Psychopharmacology, 3, 59-74.
9. Foa, E. B., & Kozak, M. J. (1986). Emotional processing of fear: Exposure to corrective information. Psychological Bulletin, 99, 20-35.
10. Hamilton, M. (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50-55.
11. Hollon, S. D., & De Rubeis, R. J. (1981). Placebo-psychotherapy combinations: Inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychological Bulletin, 90, 467-477.
12. Huitema, B. E. (1980). The analysis of covariance and alternatives. New York: Wiley.
13. Jacobson, N. S., & Ravenstorf, D. (1988). Statistics for assessing the clinical significance of psychotherapy techniques: Issues, problems and new developments. Behavioural Assessment, 10, 133-145.
14. Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. Journal of Consulting and Clinical Psychology, 59, 12-19.
15. Judd, F., Norman, T., & Burrows, G. (1990). Pharmacotherapy of panic disorder. International Review of Psychiatry, 2, 399-409.
16. Kazdin, A. E., & Bass, D. (1989). Power to detect differences between alternative treatments in comparative psychotherapy outcome research. Journal of Consulting and Clinical Psychology, 57, 138-147.
17. Kellner, R., & Sheffield, B. F. (1973). A self-rating scale of distress. Psychological Medicine, 3, 88-100.
18. Klosko, J. S., Barlow, D. H., Tassinari, R., & Cerny, J. A. (1990). A comparison of alprazolam and behaviour therapy in treatment of panic disorder. Journal of Consulting and Clinical Psychology, 58, 77-84.
19. Margraf, J., Barlow, D. H., Clark, D. M., & Telch, M. J. (1993). Psychological treatment of panic: Work in progress on outcome, active ingredients, and follow up. Behaviour Research and Therapy, 31, 1-8.
20. Marks, I. M., & Mathews, A. M. (1979). Brief standard self-rating for phobic patients. Behaviour Research and Therapy, 17, 263-267.
21. Marks, I. M., Gray, S., Cohen, S. D., Hill, R., Mawson, D., Ramm, E., & Stern, R. S. (1983). Imipramine and brief therapist aided exposure in agoraphobics having self-exposure homework. Archives of General Psychiatry, 40, 153-163.
22. Marks, I. M., Swinson, R. P., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliot, P. T., Kirby, M., McNamee, G., Sengun, S., & Wickwire, K. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. British Journal of Psychiatry, 162, 776-787.
23. McNally, R. J. (1990). Psychological approaches to panic disorder: A review. Psychological Bulletin, 108, 403-419.
24. Michelson, L., & Marchione, K. (1991). Behavioural, cognitive, and pharmacological treatments of panic disorder with agoraphobia: Critique and synthesis. Journal of Consulting and Clinical Psychology, 59, 100-114.
25. Michelson, L., Mavissakalian, M., & Marchione, K. (1985). Cognitive and behavioural treatments of agoraphobia: Clinical behavioural and psychophysiological outcomes. Journal of Consulting and Clinical Psychology, 53, 913-925.
26. Michelson, L., Marchione, K., Greenwald, M., Glanz, L., Testa, S., & Greenwald, N. (1990). Panic disorder: Cognitive behavioural treatment. Behaviour Research and Therapy, 28, 141-151.
27. Mizes, J. S., & Crawford, J. (1986). Normative values on the Marks and Mathews Fear Questionnaire: A comparison as a function of age and sex. Journal of Psychopathology and Behavioural Assessment, 8, 253-262.
28. Montgomery, S. A., & Asberg, M. (1979). A new depression rating scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382-389.
29. Power, K. G., Jerrom, D. W. A., Simpson, R. J., & Mitchell, M. (1985). Controlled study of withdrawal symptoms and rebound anxiety after six weeks course of diazepam for generalised anxiety. British Medical Journal, 290, 1246-1248.
30. Power, K. G., & Sharp, D. M., (1995). Keep taking the tablets? Inadequate controls for concurrent psychotropic medication in studies of psychological treatments for panic disorder. Journal of Psychopharmacology, 9, 70-71.
31. Power, K. G., Simpson, R. J., Swanson, V., Wallace, L. A., Feistner, A. T. G., & Sharp, D. (1990). A controlled comparison of cognitive behaviour therapy, diazepam, and placebo, alone and in combination for the treatment of generalised anxiety disorder. Journal of Anxiety Disorders, 4, 267-292.
32. Shear, M. K., & Frances, A. (1988). Panic disorder: clinical presentation and evaluation. Psychiatric Annals, 18, 448-457.
33. Simpson, R. J., Kazmierczak, T., Power, K. G., & Sharp, D. M. (1994). Controlled comparison of the characteristics of patients with panic disorder. British Journal of General Practice, 44, 352-356.
34. Telch, M. J., Agras, W. S., Taylor, C. B., Roth, W. T., & Gallen, C. (1985). Combined pharmacological and behavioural treatment for agoraphobia. Behaviour Research and Therapy, 23, 325-335.
35. Tyrer, P., Candy, J., & Kelly, D. (1973). A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia, 32, 237-254.
36. Weissman, M. (1988). The epidemiology of anxiety disorders: Rates, risks and familial patterns. Journal of Psychiatric Research, 22, 99-114.
37. Weissman, M. (1991). Panic disorder: impact on quality of life. Journal of Clinical Psychiatry, 52, 6-9.
38. Wilkinson, G., & Lewis, G. (1990). The public health impact of panic. In D. Goth & N. L. M. Goeting (Eds.), Panic: symptom or disorder? (pp. 2-14). Duphar Medical Relations: Duphar Laboratories Ltd.
39. Zinbarg, R. E., Barlow, D. H., Brown, T. A., & Hertz, R. M. (1992). Cognitive behavioural approaches to the nature and treatment of anxiety disorders. Annual Review of Psychology, 43, 235-267.